Sugi Predict

Sugi Predict / Compounds / SCHEMBL4867374

SCHEMBL4867374

SCHEMBL4867374

NC(=O)CN(c1ccc(Cl)cc1Cc1ccccc1Cl)S(=O)(=O)c1cccc(N)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 9/20 0.43
▸ NFE2L2 Q16236 9/20 0.43
▸ THRB P10828 2/20 0.39
▸ PTGER1 P34995 1/20 0.38
▸ KCNJ6 P48051 1/20 0.37
▸ KCNJ5 P48544 1/20 0.37
▸ KCNJ3 P48549 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ PKM P14618 2/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ TP53 P04637 1/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249159 0.91 KEAP1 (0.48) KEAP1NFE2L2THRBPTGER1PKM
SCHEMBL3247110 0.89 THRB (0.45) KEAP1NFE2L2THRBPTGER1KCNJ6
SCHEMBL3253245 0.89 KEAP1 (0.51) KEAP1NFE2L2THRBPTGER1PKM
SCHEMBL3255563 0.89 KEAP1 (0.53) KEAP1NFE2L2PTGER1PKMMEN1
SCHEMBL3255469 0.88 KEAP1 (0.43) KEAP1NFE2L2THRBPTGER1PKM
SCHEMBL13357726 0.88 KEAP1 (0.48) KEAP1NFE2L2THRBCYP3A4CYP2C9
SCHEMBL3251187 0.87 THRB (0.44) KEAP1NFE2L2THRBPTGER1PKM
SCHEMBL3252244 0.87 MAPT (0.44) KEAP1NFE2L2MEN1KMT2ATP53
SCHEMBL4869119 0.86 KEAP1 (0.38) KEAP1NFE2L2THRBPTGER1KCNJ5
SCHEMBL4871469 0.86 FLT1 (0.45) KEAP1NFE2L2PKMKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 — — EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 — — US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 — — US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 — — US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 — — US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 — — US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 — — US disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 KEAP1 3317/4885NFE2L2 2700/4885THRB 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.